drugset / Trial / NCT00646529

Long-Term Safety of Symbicort in Asthmatic Children - SAPLING

NCT00646529

Phase 3 Completed 175 enrolled AstraZeneca
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the safety of Symbicort compared to Pulmicort in asthmatic children aged 6 to 11 years

Timeline

Start
2002-07
Primary completion
Completion
2003-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Budesonide Small molecule
Subject budesonide/formoterol Unknown

Indications